This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bröijersén, A. Articles by Hjemdahl, P. Search for Related Content PubMed PubMed Citation Articles by Bröijersén, A. Articles by Hjemdahl, P.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:121-127.)
© 1995 American Heart Association, Inc.

Articles

Gemfibrozil Enhances Platelet Activity in Patients With Combined Hyperlipoproteinemia

Anders Bröijersén; Mats Eriksson; Bo Angelin; Paul Hjemdahl

From the Departments of Clinical Pharmacology (A.B., P.H.) and Physiology and Pharmacology (A.B.), Karolinska Institute, and the Metabolism Unit, Department of Medicine, Karolinska Institute at Huddinge University Hospital (M.E., B.A.), Stockholm, Sweden.

Correspondence to Paul Hjemdahl, MD, PhD, Department of Clinical Pharmacology, Karolinska Hospital, S-171 76 Stockholm, Sweden.

Abstract A placebo-controlled crossover study was conducted to evaluate whether lipid-lowering with gemfibrozil (10 to 12 weeks) affects platelet function in vivo at rest and during mental stress in 21 men with combined hyperlipoproteinemia. Gemfibrozil lowered plasma triglycerides and total and VLDL cholesterol (P<.001 for all), whereas HDL cholesterol increased (P<.001). Gemfibrozil increased platelet counts by 18% (P<.001) and, according to filtragometry measurements, enhanced overall (means of rest and stress values) platelet aggregability in vivo (P=.014); this effect was more evident during mental stress (P=.027) than at rest (P=.18). Moreover, the urinary excretion of 11-dehydro-thromboxane-B₂ was 54% higher during treatment with gemfibrozil (P<.001), whereas the excretion of ß-thromboglobulin in urine was unaltered. Plasma ß-thromboglobulin tended to be slightly elevated during active treatment (P=.15). Mental stress increased heart rate and catecholamine levels and elevated all cholesterol fractions (P<.01) and plasma ß-thromboglobulin (during placebo, P=.02), but platelet aggregability did not increase significantly. A positive correlation was found between 11-dehydro-thromboxane-B₂ excretion and LDL cholesterol levels during placebo (r=.62, P=.0057). In conclusion, gemfibrozil has beneficial effects on plasma lipoprotein levels but enhances several aspects of platelet activity in vivo and increases platelet counts. These changes might be prothrombotic and thus adverse for the hyperlipidemic patient. Primary preventive effects of gemfibrozil might be enhanced if a platelet inhibitor such as aspirin is administered with gemfibrozil.

Key Words: hyperlipoproteinemia • lipoproteins • gemfibrozil • ß-thromboglobulin • platelet function • filtragometry • thromboxane

This article has been cited by other articles:

				A. Broijersen, M. Eriksson, B. Leijd, B. Angelin, and P. Hjemdahl No Influence of Simvastatin Treatment on Platelet Function In Vivo in Patients With Hypercholesterolemia Arterioscler Thromb Vasc Biol, February 1, 1997; 17(2): 273 - 278. [Abstract] [Full Text]